WO2012014630A1 - アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法 - Google Patents
アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法 Download PDFInfo
- Publication number
- WO2012014630A1 WO2012014630A1 PCT/JP2011/065228 JP2011065228W WO2012014630A1 WO 2012014630 A1 WO2012014630 A1 WO 2012014630A1 JP 2011065228 W JP2011065228 W JP 2011065228W WO 2012014630 A1 WO2012014630 A1 WO 2012014630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- astaxanthin
- acid
- salt
- aqueous composition
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
Definitions
- the present invention relates to an astaxanthin-containing aqueous composition, a cosmetic, and a method for inhibiting astaxanthin degradation.
- Astaxanthin is a naturally-occurring carotenoid that is also known to have functions such as an antioxidant effect and an anti-inflammatory effect, and is added to foods, cosmetics, pharmaceuticals and other processed products.
- JP 2000-136123 A discloses an external preparation for skin containing astaxanthin santine as an active oxygen remover.
- Japanese Patent Application Laid-Open No. 2002-128651 discloses a photoaging inhibitor containing astaxanthin santin as a component having a singlet oxygen scavenging ability.
- Japanese Patent Application Laid-Open No. 9143063 discloses a composition containing an astaxanthin and a medicinal agent.
- JP-A-6-264055 discloses a method of adding an organic acid to a carotenoid-containing material.
- JP 2008-74717 A contains carotenoids and deoxygenated water and an iron chelating agent in order to suppress impurities contained in the carotenoid-containing emulsion composition and odor due to oxidation and to improve stability over time. Is disclosed.
- An object of the first aspect of the present invention is to provide an astaxanthin-containing aqueous composition excellent in the temporal stability of the contained astaxanthin, and a cosmetic containing the same.
- Another object of the second aspect of the present invention is to provide a method for suppressing astaxanthin degradation.
- the iron chelator is an iron chelator, citric acid or a salt thereof, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, etidronic acid or a salt thereof, diethylenetriaminepentaacetic acid (DTPA or a salt thereof), hydroxyethylenediaminetriacetic acid ⁇ 1> selected from the group consisting of (HEDTA) or a salt thereof, ethylenediamine-N, N, N ′, N′-tetramethylenephosphonic acid (EDTMP) or a salt thereof, and tartaric acid or a salt thereof Alternatively, the astaxanthin-containing aqueous composition according to ⁇ 2>.
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- hydroxyethylenediaminetriacetic acid ⁇ 1> selected from the group consisting of (HEDTA) or a salt thereof, ethylenediamine-N, N, N ′, N
- ⁇ 4> The astaxanthin-containing aqueous composition according to any one of ⁇ 1> to ⁇ 3>, further comprising a water-soluble antioxidant.
- ⁇ 5> A cosmetic comprising the astaxanthin-containing aqueous composition according to any one of ⁇ 1> to ⁇ 4>.
- the iron chelating agent is citric acid or a salt thereof, ethylenediaminetetraacetic acid (EDTA), etidronic acid, diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), ethylenediamine-N, N, N ′, N
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- HEDTA hydroxyethylenediaminetriacetic acid
- ethylenediamine-N, N, N ′, N The method for inhibiting astaxanthin degradation according to ⁇ 6> or ⁇ 7>, which is at least one selected from the group consisting of '-tetramethylenephosphonic acid (EDTMP) and tartaric acid.
- EDTMP '-tetramethylenephosphonic acid
- aqueous composition further contains a water-soluble antioxidant.
- the astaxanthin containing aqueous composition excellent in the temporal stability of the astaxanthin contained, and the cosmetics containing this can be provided.
- a method for suppressing astaxanthin degradation can be provided.
- the astaxanthin-containing aqueous composition of the present invention contains at least astaxanthin, 20 ⁇ g / L or more of iron ions, and an iron chelating agent.
- the astaxanthin-containing aqueous composition of the present invention has the above-described configuration, the decomposition of astaxanthin contained in the composition is effectively suppressed, and the stability over time is dramatically improved. This is based on the knowledge obtained by the present inventor that the decomposition of an iron ion coexisting in an aqueous composition containing astaxanthin at a specific amount or more is significantly accelerated.
- iron ions One of the factors that cause iron ions to be mixed in the aqueous composition is contamination by iron components contained as impurities contained in the manufacturing raw material.
- dipropylene glycol which is a kind of polyhydric alcohol, is a component used for raw materials such as cosmetics as a component for imparting a moisturizing function, a viscosity adjusting function, etc., but tends to contain iron ions as impurities. large.
- iron ions can be mixed into the composition by elution from a stainless steel kettle or piping during production.
- the astaxanthin-containing aqueous composition of the present invention is preferably an oil-in-water emulsion composition.
- the “aqueous system” means a system containing at least 50% by mass of water and / or a water-soluble solvent.
- a numerical range indicated by using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
- the amount of each component in the composition when there are a plurality of substances corresponding to each component in the composition, the plurality present in the composition unless otherwise specified. Means the total amount of substances.
- aqueous composition of the present invention various components included in the aqueous composition of the present invention are essential and optional.
- Astaxanthin contained in the aqueous composition of the present invention has an antioxidant effect, an anti-inflammatory effect, a skin aging prevention effect, a whitening effect, etc., and has an excellent emollient effect, skin aging prevention effect and antioxidant effect. It is known as a component capable of imparting.
- “astaxanthin” includes both astaxanthin and derivatives of astaxanthin and the like (hereinafter also referred to as “astaxanthins” as appropriate).
- Astaxanthin in the present invention may be any as long as it is obtained according to a conventional method in addition to those derived from natural products such as plants, algae and bacteria.
- natural products such as plants, algae and bacteria.
- the natural product include red yeast faffia, green algae hematococcus, marine bacteria, and krill.
- the extract from the culture etc. can be mentioned. Astaxanthin may be contained in the aqueous composition of the present invention as an astaxanthin-containing oil separated and extracted from a natural product containing astaxanthin (and may be appropriately purified as necessary).
- astaxanthin-containing oil examples include red yeast paffia, green algae hematococcus, marine bacteria, and the like, and extracts from the culture, extracts from Antarctic krill, and the like. It is known that the Haematococcus alga extract (haematococcus alga-derived pigment) differs from the krill-derived pigment and the synthesized astaxanthin in terms of the type of ester and its content.
- the astaxanthins in the present invention may be the above-described extract, or a product obtained by appropriately purifying the extract as necessary, or a synthetic product.
- those extracted from Haematococcus alga also referred to as Haematococcus alga extract
- Haematococcus alga extract are particularly preferred from the viewpoint of quality and productivity.
- Haematococcus alga extract that can be used in the present invention
- Haematococcus pluvialis Haematococcus lacustris
- Haematococcus capustis Haematococcus capustis
- Hematococcus capensis examples thereof include Haematococcus droebakensis and Haematococcus zimbabwiensis.
- Haematococcus alga extract can be used.
- ASTOTS-S ASTOTS-2.5 O
- ASTOTS-5 O ASTOTS-5 O
- SA ASTOT-10 O all trade names
- Fuji Chemical Industry Co., Ltd. Asteril Oil 50F
- Asteryl Oil 5F all trade names
- Toyo Enzyme Chemical Co., Ltd. BioAstin SCE7 product) Name
- the content of astaxanthin as a pure pigment content in the Haematococcus alga extract that can be used in the present invention is preferably 0.001% by mass to 50% by mass from the viewpoint of handling during the production of the aqueous composition. More preferably, the content is 0.01% by mass to 25% by mass.
- the Haematococcus alga extract that can be used in the present invention contains astaxanthin or an ester thereof as a pure component of the pigment as described in JP-A-2-49091. 50 mol% or more, preferably 75 mol% or more, more preferably 90% mol or more. Further details are described in “Astaxanthin Chemistry”, 2005, Internet ⁇ URL: http://www.astaxanthin.co.jp/chemical/basic.htm>.
- the aqueous composition of the present invention contains 20 ⁇ g / L or more of iron ions.
- the aqueous composition containing astaxanthin contains 20 ⁇ g / L or more of iron ions
- the decomposition of astaxanthin is remarkably advanced, and the temporal stability of the aqueous composition is impaired to a practical level.
- the inclusion of 50 ⁇ g / L or more of iron ions will cause the decomposition of astaxanthin to such an extent that the effect of the inclusion of astaxanthin is hardly obtained, but the aqueous composition of the present invention has such an amount of iron. Even when it contains ions, it exhibits excellent stability over time.
- the upper limit is 200 microgram / L.
- the amount of iron ions contained in the aqueous composition of the present invention is a value measured by HR-ICP-MS (ELFENT-XR, trade name, manufactured by Thermo Fisher).
- Iron chelating agent contained in the aqueous composition of the present invention may be any compound that can form a chelate bond with iron ions.
- iron chelating agent examples include citric acid or its salt, ethylenediaminetetraacetic acid (EDTA) or its salt, etidronic acid or its salt, diethylenetriaminepentaacetic acid (DTPA) or its salt, hydroxyethylenediaminetriacetic acid (HEDTA) or its salt , Ethylenediamine-N, N, N ′, N′-tetramethylenephosphonic acid (EDTMP) or a salt thereof, tartaric acid or a salt thereof, phytic acid or a salt thereof, pyrophosphoric acid or a salt thereof, polyphosphoric acid or a salt thereof, metaphosphoric acid or From the viewpoint of not causing precipitation due to complex salts, citric acid or a salt thereof, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, etidronic acid or a salt thereof, diethylenetriaminepentaacetic acid (DTPA or a salt thereof).
- EDTA ethylenediamine
- HEDTA hydroxyethylenediaminetriacetic acid
- ETMP ethylenediamine-N, N, N ′, N′-tetramethylenephosphonic acid
- EDTMP ethylenediamine-N, N, N ′, N′-tetramethylenephosphonic acid
- EDTMP ethylenediamine-N, N, N ′, N′-tetramethylenephosphonic acid
- tartaric acid or a salt thereof One is preferable, citric acid or a salt thereof, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, and etidronic acid or a salt thereof are more preferable, and etidronic acid or a salt thereof is more preferable.
- the iron chelating agent contained in the aqueous composition may be only one kind or two or more kinds.
- the content of the iron chelating agent is preferably 0.5 mol times to 10 mol times, preferably 0.7 mol times to 5 mol times with respect to the iron ions present in the aqueous composition, from the viewpoint of the ability to sequester iron ions. Is more preferably 1 to 3 times.
- the content of the iron chelating agent with respect to the total mass of the aqueous composition is preferably in the range of 0.001% by mass to 10% by mass, more preferably in the range of 0.01% by mass to 3% by mass, and 0.1% by mass. A range of 1% by mass to 1% by mass is more preferable.
- the aqueous composition of the present invention further contains a water-soluble antioxidant.
- a water-soluble antioxidant By containing a water-soluble antioxidant, the temporal stability of the aqueous composition can be further improved.
- water-soluble antioxidant for example, a known water-soluble antioxidant can be applied.
- Suitable water-soluble antioxidants include, for example, (I) ascorbic acid or ascorbic acid derivatives or their salts, and erythorbic acid or erythorbic acid derivatives or their salts, (II) polyphenols A group of compounds can be mentioned.
- Ascorbic acid or an ascorbic acid derivative or a salt thereof and a group of compounds consisting of erythorbic acid or an erythorbic acid derivative or a salt thereof Ascorbic acid or an ascorbic acid derivative or a salt thereof includes L-ascorbic acid, L-ascorbic acid Acid Na, L-ascorbic acid K, L-ascorbic acid Ca, L-ascorbic acid phosphate, magnesium salt of L-ascorbic acid phosphate, L-ascorbic acid sulfate, L-ascorbic acid sulfate disodium salt L-ascorbic acid stearate, L-ascorbic acid 2-glucoside, L-ascorbyl palmitate, tetraisopalmitate L-ascorbyl and the like.
- the magnesium salt of L-ascorbic acid phosphate is particularly preferred.
- erythorbic acid or erythorbic acid derivatives or salts thereof include erythorbic acid, erythorbic acid Na, erythorbic acid K, erythorbic acid Ca, erythorbic acid phosphate, erythorbic acid sulfate, and the like.
- water-soluble antioxidant belonging to the compound group (I) commercially available products can be appropriately used.
- L-ascorbic acid available from Takeda Pharmaceutical, Fuso Chemical, BASF Japan, Daiichi Pharmaceutical, etc.
- L-ascorbic acid Na available from Takeda Pharmaceutical, Fuso Chemical, BASF Japan, Daiichi Pharmaceutical, etc.
- Ascorbic acid 2-glucoside Wako Pure Chemicals, trade name: AA-2G (available from Hayashibara Biochemical Research Institute)
- L-ascorbic acid phosphate Mg (trade name: PM "SDK” ascorbic acid (from Showa Denko)
- Product name: Seamate available from Takeda Pharmaceutical
- Ascorbyl palmitate Provide
- the compound group consisting of polyphenols includes flavonoids (catechin, anthocyanin, flavone glycoside, isoflavone glycoside, flavan glycoside, flavanone, rutin glycoside), phenolic acids (Chlorogenic acid, ellagic acid, gallic acid, propyl gallate), lignan glycosides, curcumin glycosides, coumarins and the like. Moreover, since these compounds are contained in a large amount in extracts derived from natural products, they can be used in the state of extracts.
- water-soluble antioxidant belonging to the compound group (II) commercially available products can be appropriately used.
- ellagic acid available from Wako Pure Chemical Industries, Ltd.
- rosemary extract trade names: RM-21A, RM-21E, available from Mitsubishi Chemical Foods, Inc.
- catechin trade name: Sankatole W-5) No.
- ascorbic acid or ascorbic acid derivatives are particularly preferable from the viewpoint of the strength of antioxidant ability.
- the content of the water-soluble antioxidant in the aqueous composition of the present invention is preferably 0.1% by mass to 6% by mass, more preferably 0.5% by mass to 5% by mass with respect to the total mass of the aqueous composition. %, More preferably 1% by mass to 3% by mass.
- the aqueous composition of the present invention may further contain a polyhydric alcohol.
- the polyhydric alcohol has a moisturizing function and a viscosity adjusting function.
- the polyhydric alcohol reduces the interfacial tension between water and the oil and fat component, facilitates widening of the interface, and is fine and stable. It also has the function of facilitating the formation of emulsion composition particles. Therefore, when the aqueous composition of the present invention contains a polyhydric alcohol, when the aqueous composition of the present invention is configured as an emulsion composition, the particle size of the emulsion composition becomes smaller and the particle size is reduced. Is preferable from the viewpoint of being stably maintained over a long period in a small state. Moreover, the addition of polyhydric alcohol can reduce the water activity of the aqueous composition of the present invention, and can suppress the growth of microorganisms.
- the polyhydric alcohol that can be contained in the aqueous composition of the present invention is not particularly limited as long as it is a dihydric or higher alcohol.
- the polyhydric alcohol include glycerin, diglycerin, triglycerin, polyglycerin, 3-methyl-1,3-butanediol, 1,3-butylene glycol, isoprene glycol, polyethylene glycol, 1,2-pentanediol, 1,2-hexanediol, propylene glycol, dipropylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, pentaerythritol, neopentyl glycol, maltitol, reduced starch syrup, sucrose, lactitol, palatinit, erythritol, sorbitol, mannitol, xylitol, xylose Glucose, lactose, mannose, maltose, galact
- dipropylene glycol tends to contain a lot of iron ions as impurities in the production process, and it is easy to introduce iron ions into the aqueous composition.
- the aqueous composition of the present invention exhibits excellent temporal stability because the decomposition of astaxanthin is suppressed even when such a polyhydric alcohol is used.
- the polyhydric alcohol it is preferable to use one having 3 or more hydroxyl groups in one molecule.
- the interfacial tension between the aqueous solvent and the fat component can be reduced more effectively, and finer and more stable fine particles can be obtained. Can be formed.
- the aqueous composition of the present invention is used for food, for example, the intestinal absorptivity can be increased, and for transdermal pharmaceutical applications and cosmetic applications, the skin absorbability can be increased.
- the content of the polyhydric alcohol in the aqueous composition of the present invention is preferably 10% by mass to 60% by mass, preferably 20% by mass to 55% by mass, and more preferably 30% by mass with respect to the total mass of the aqueous composition. 50% by mass. If the content of the polyhydric alcohol is 10% by mass or more, sufficient stability over time can be obtained regardless of the type and content of the oil-soluble component. On the other hand, when the content of the polyhydric alcohol is 60% by mass or less, the intended effect can be obtained while adjusting the viscosity of the emulsion composition composition to an appropriate range.
- Emulsifier When the water-based composition of the present invention is configured as an oil-in-water emulsion composition which is a preferred embodiment thereof, it preferably contains an emulsifier.
- the emulsifier is not particularly limited, but a nonionic emulsifier is preferable.
- the nonionic emulsifier include glycerin fatty acid ester, organic acid monoglyceride, polyglycerin fatty acid ester, propylene glycol fatty acid ester, polyglycerin condensed ricinoleic acid ester, sorbitan fatty acid ester, and sucrose fatty acid ester. More preferred examples are polyglycerin fatty acid ester, sorbitan fatty acid ester, and sucrose fatty acid ester.
- the emulsifier is not necessarily highly purified by distillation or the like, and may be a reaction mixture.
- polyglycerol fatty acid ester examples include polyglycerol having an average degree of polymerization of 2 or more, preferably 6 to 15, more preferably 8 to 10 and fatty acid having 8 to 18 carbon atoms, such as caprylic acid, capric acid, lauric acid, myristic. Esters with acids, palmitic acid, stearic acid, oleic acid, and linoleic acid.
- polyglycerol fatty acid esters include hexaglycerol monooleate, hexaglycerol monostearate, hexaglycerol monopalmitate, hexaglycerol monomyristate, hexaglycerol monolaurate, decaglycerol monooleate , Decaglycerin monostearic acid ester, decaglycerin monopalmitic acid ester, decaglycerin monomyristic acid ester, decaglycerin monolauric acid ester and the like. These polyglycerin fatty acid esters can be used alone or in combination.
- NIKKOL DGMS NIKKOL DGMO-CV
- NIKKOL DGMO-90V NIKKOL DGDO
- NIKKOL DGMIS NIKKOL DGTI
- NIKGL DGTIS NIKOLGTL Tetraglyn 3-S
- NIKKOL Tetraglyn 5-S NIKKOL Tetraglyn 5-O
- NIKKOL Hexaglyn 1-L NIKKOL Hexaglyn 1-M
- NIKKOL Hexaglyn 1-SV NIKKOL Hexaglyn 1-SV
- NIKKOL Hexaglyn 1-O NIKKOL Hexaglyn 3-S
- NIKKOL Hexaglyn 4 -B IKKOL Hexaglyn 5-S, NIKKOL Hexaglyn 5-O, NIKKOL Hexaglyn PR-15, NIKKOL Decaglyn 1-L, NIKKOL Decaglyn 1-L, NIKKOL Dec
- the sorbitan fatty acid ester preferably has 8 or more carbon atoms, more preferably 12 or more.
- Preferred examples of the sorbitan fatty acid ester include sorbitan monocaprylate, sorbitan monolaurate, sorbitan monostearate, sorbitan tristearate, sorbitan tristearate, sorbitan isostearate, sorbitan sesquiisostearate, sorbitan oleate, sorbitan sesquioleate And sorbitan trioleate.
- These sorbitan fatty acid esters can be used alone or in combination.
- sucrose fatty acid ester those having 12 or more carbon atoms of fatty acids are preferable, and those having 12 to 20 carbon atoms are more preferable.
- Preferred examples of sucrose fatty acid esters include sucrose dioleate, sucrose distearate, sucrose dipalmitate, sucrose dimyristic ester, sucrose dilaurate, sucrose monooleate, sucrose Examples thereof include sugar monostearate, sucrose monopalmitate, sucrose monomyristate, and sucrose monolaurate. In the present invention, these sucrose fatty acid esters can be used alone or in combination.
- Examples of commercially available products include Ryoto Sugar Esters S-070, S-170, S-270, S-370, S-370F, S-570, S-770, S-970, manufactured by Mitsubishi Chemical Foods Corporation.
- the amount added when using the above-mentioned emulsifier is preferably 0.1% by mass to 50% by mass, more preferably 0.5% by mass to 20% by mass, and still more preferably mass, relative to the total mass of the composition. % To 15% by mass.
- lecithin is also effective.
- Lecithin is a substance in which a glycerin skeleton, a fatty acid residue and a phosphate residue are essential constituents, to which a base, a polyhydric alcohol and the like are bonded, and is also called a phospholipid. Since lecithin has a hydrophilic group and a hydrophobic group in the molecule, it has been widely used as an emulsifier in the food, pharmaceutical and cosmetic fields.
- lecithin having a purity of 60% or more is used as lecithin and can be used in the present invention.
- the lecithin is preferably generally referred to as high-purity lecithin, which has a lecithin purity of 80% or more, more preferably 90% or more.
- the lecithin purity is determined by subtracting the weight of the toluene-insoluble matter and the acetone-soluble matter using the property that lecithin is easily dissolved in toluene and not dissolved in acetone.
- lecithin examples include various conventionally known ones extracted and separated from plants, animals and microorganisms. Specific examples of such lecithin include various lecithins derived from plants such as soybean, corn, peanut, rapeseed and wheat, animals such as egg yolk and cattle, and microorganisms such as Escherichia coli.
- lecithin When such a lecithin is represented by a compound name, for example, glycerolecithin such as phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, bisphosphatidic acid, diphosphatidylglycerol (cardiolipin); Examples include sphingolecithin such as sphingomyelin.
- glycerolecithin such as phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, bisphosphatidic acid, diphosphatidylglycerol (cardiolipin);
- sphingolecithin such as sphingomyelin.
- hydrogenated lecithin enzymatically decomposed lecithin, enzymatically decomposed hydrogenated lecithin, hydroxylecithin, and the like can be used in addition to the above high-purity lecithin.
- lecithins can be used alone or in the form of a mixture of plural kinds.
- the content thereof is preferably 0.1% by mass to 10% by mass, more preferably 0.2% by mass to 5% by mass, and still more preferably based on the total mass of the composition. 0.5% by mass to 2% by mass.
- oily component that can be used in the present invention is not particularly limited as long as it is a component that is insoluble or hardly soluble in water and soluble in an oily medium.
- the term “insoluble in an aqueous medium” means that the solubility in 100 mL of an aqueous medium is 0.01 g or less at 25 ° C.
- the term “insoluble in an aqueous medium” means that the solubility in 100 mL of an aqueous medium is 0 at 25 ° C. It means exceeding 0.1 g and 0.1 g or less.
- the “functional component” in the present specification means a component that can be expected to induce a predetermined physiological effect in the applied living body when applied to the living body.
- oils and fats examples include a wide range of oil components that exhibit useful effects when used in cosmetics.
- oils and fats hydrocarbons, waxes, esters, higher alcohols, polymers, oil-soluble pigments, oil-soluble proteins and the like.
- various vegetable oils and animal oils which are mixtures thereof are also included.
- oils and oils such as coconut oil, olive oil, corn oil and jojoba oil; higher alcohols such as behenyl alcohol, stearyl alcohol and cetanol; sterols such as cholesterol and phytosterol; ethylhexyl palmitate, myristic acid
- esters such as isopropyl and octyldodecyl myristate; hydrocarbons such as squalane, hydrogenated polydecene, and hydrogenated polyisobutene.
- carotenoids such as ⁇ -carotene, zeaxanthin, lycopene, lutein, vitamin E such as tocopherol and tocotrienol, ubiquinones such as coenzyme Q10, EPA, DHA, linolenic acid, etc.
- Omega-3 oils and the like can also be included.
- active ceramides such as ceramide I, ceramide II, ceramide III, ceramide V and ceramide VI; glycosphingolipids such as glucosylceramide and galactosylceramide; sphingomyelins Pseudo-ceramides can also be included.
- the content of the other oil component is preferably 0.1% by mass to 50% by mass, more preferably 0.2% by mass to 25%, based on the total mass of the composition. % By mass, more preferably 0.5% by mass to 10% by mass. If the content of the oil component is 0.1% by mass or more, the effectiveness of the active ingredient can be sufficiently exerted, and the aqueous composition of the present invention is preferably applied to cosmetics. On the other hand, if it is 50 mass% or less, since the increase in a dispersed particle diameter and the deterioration of emulsification stability are suppressed and a stable composition is obtained, it is preferable.
- the method for inhibiting astaxanthin degradation of the present invention is a method for inhibiting astaxanthin degradation applied to an aqueous composition containing astaxanthin. At least in the aqueous composition containing astaxanthin and iron ions of 20 ⁇ g / L or more, It is characterized by containing an iron chelating agent.
- the method for producing an aqueous composition to which the decomposition inhibiting method of the present invention is applied is not particularly limited, but it is preferable to have at least a step of forming an emulsion composition by mixing astaxanthin and an iron chelating agent.
- an iron chelating agent, a water-soluble emulsifier, a water-soluble antioxidant, and a polyhydric alcohol are dissolved in an aqueous medium to obtain an aqueous phase
- b) astaxanthin, an oil-soluble emulsifier, an oil-soluble antioxidant and necessary are mixed and dissolved to obtain an oil phase
- c) the water phase and the oil phase are mixed with stirring, emulsified and dispersed to obtain an emulsion composition. preferable.
- an astaxanthin-containing emulsion composition having a high concentration is prepared and diluted with an aqueous solvent such as water, an aqueous component such as an iron chelator, a polyhydric alcohol, or a water-soluble antioxidant may be added. it can.
- an aqueous component such as an iron chelator, a polyhydric alcohol, or a water-soluble antioxidant.
- the dilution ratio of the high-concentration astaxanthin-containing emulsion composition can be selected as appropriate, preferably 10 to 200 times, more preferably 20 to 150 times, and even more preferably 40 times. More preferably, it is 100 times or less.
- the emulsion is emulsified using a normal emulsifier using a shearing action such as a stirrer, impeller stirring, a homomixer, or a continuous flow shearing device, and then passed through a high-pressure homogenizer. It is particularly preferable to use more than one type of emulsifier.
- a high-pressure homogenizer By using a high-pressure homogenizer, the emulsion can be arranged into even more uniform droplets of fine particles. Further, the emulsification dispersion may be performed a plurality of times for the purpose of forming droplets having a more uniform particle diameter.
- the high-pressure homogenizer examples include a chamber-type high-pressure homogenizer having a chamber in which a flow path for processing liquid is fixed and a homogeneous-valve high-pressure homogenizer having a homogeneous valve.
- the homogeneous valve type high-pressure homogenizer can easily adjust the width of the flow path of the processing liquid, so the pressure and flow rate during operation can be set arbitrarily, and the operation range is wide. In particular, it is widely used in the emulsification field such as food and cosmetics.
- a chamber type high-pressure homogenizer is used for applications that require ultra-high pressure because a mechanism for increasing pressure is easy to make.
- Chamber type high-pressure homogenizers include microfluidizer (trade name, manufactured by Microfluidics), nanomizer (trade name, manufactured by Yoshida Kikai Kogyo Co., Ltd.), and optimizer (trade name, manufactured by Sugino Machine Co., Ltd.). Can be mentioned.
- Homogeneous valve type high-pressure homogenizers include Gorin type homogenizers (trade name, manufactured by APV), Lanier type homogenizers (trade name, manufactured by Lanier), high-pressure homogenizers (trade name, manufactured by Niro Soavi), and homogenizers (Sanwa Machinery). (Trade name), high-pressure homogenizer (trade name, manufactured by Izumi Food Machinery Co., Ltd.), and ultra-high pressure homogenizer (trade name, manufactured by Ika).
- the dispersion by the high-pressure homogenizer is considered to be due to a large shear force generated when the liquid passes through a very narrow (small) gap at a high speed.
- the magnitude of this shearing force is approximately proportional to the pressure, and the higher the pressure is, the stronger the shearing force applied to the particles dispersed in the liquid, that is, the dispersion force.
- the higher the pressure the higher the temperature of the liquid, which may promote the deterioration of the dispersion components and the reaggregation of the particles. .
- the pressure of the homogenizer is preferably 50 MPa or more, more preferably 50 MPa to 250 MPa, still more preferably 100 MPa to 250 MPa.
- the emulsion is preferably cooled through some cooler within 30 seconds, preferably within 3 seconds immediately after passing through the chamber.
- ultrasonic homogenizers include ultrasonic homogenizers US-1200T, RUS-1200T, MUS-1200T (trade name, manufactured by Nippon Seiki Seisakusho Co., Ltd.), ultrasonic processors UIP2000, UIP-4000, UIP-8000, UIP-16000 (trade name, manufactured by Heelscher, Inc.) and the like.
- the frequency is 25 kHz or less, preferably 15 to 20 kHz
- the energy density of the dispersed portion is 100 W / cm 2 or more, preferably 120 W / cm 2.
- fine emulsification may be performed.
- the batch irradiation may be used for the ultrasonic irradiation, but in that case, it is preferably used in combination with a means for stirring the entire dispersion.
- stirring such as an agitator, a magnetic stirrer, or a disper is used.
- flow-type ultrasonic irradiation can be performed.
- the flow type means that a dispersion liquid supply tank and a supply pump are provided, and the dispersion liquid is sent into a chamber having an ultrasonic irradiation unit at a constant flow rate. Supply of the liquid to the chamber is effective in any direction, but a method of supplying the liquid in a direction in which the liquid flow collides perpendicularly to the ultrasonic irradiation surface is particularly preferable.
- the time during which the ultrasonic irradiation is performed is not particularly limited, but is preferably the time during which the ultrasonic wave is irradiated in the container, and is preferably 2 minutes / kg to 200 minutes / kg. If it is too short, emulsification is insufficient, and if it is too long, reaggregation may occur.
- the optimum time varies depending on the emulsion, but is generally preferably between 10 minutes and 100 minutes.
- the irradiation container can be cooled from the outside, or a cooling unit can be installed in the container.
- a cooling means such as a heat exchanger in the middle of the flow circulation in addition to cooling the ultrasonic irradiation chamber from the outside.
- a more preferable dispersion can be obtained when an ultrasonic homogenizer is used in combination with an ultrahigh pressure homogenizer. That is, after emulsification using a normal emulsifier using a shearing action, ultra-high pressure homogenizer dispersion is performed to increase the efficiency of ultra-high pressure homogenizer dispersion, thereby reducing the number of passes and reducing coarse particles. A high-quality emulsion can be obtained. Moreover, after performing ultrahigh pressure homogenizer emulsification, coarse particles can be reduced by further performing ultrasonic irradiation. Also, these steps can be repeated in any order, such as alternately performing ultra-high pressure dispersion and ultrasonic irradiation.
- the aqueous composition of the present invention is excellent not only in various functions due to astaxanthin but also in stability over time. For this reason, it is preferably used as it is or as a component material for various uses depending on the functions of astaxanthin and other components contained in the composition.
- Examples of such applications include a wide range of uses such as pharmaceuticals (external preparations, skin preparations), cosmetics, and foods.
- pharmaceuticals are known as parenterals such as suppositories and coating agents (skin external preparations)
- cosmetics are known as water-based cosmetics such as lotions, cosmetic liquids, gels, emulsions, creams and the like. Any aspect of the general dosage form may be used.
- astaxanthin-containing dispersion of the present invention is used in an external preparation for skin and cosmetics, components that can be added to pharmaceuticals and cosmetics can be appropriately added as necessary.
- the mixture was stirred with a homogenizer (10000 rpm), and the oil phase was added thereto to obtain an emulsion.
- the obtained emulsion was subjected to high-pressure emulsification using an optimizer HJP-25005 (trade name, manufactured by Sugino Machine Co., Ltd.) at a pressure of 200 MPa. Thereafter, the emulsion was filtered through a microfilter having an average pore size of 1 ⁇ m to prepare an astaxanthin-containing emulsion composition K-01.
- each component used for the water phase composition and the oil phase composition is as follows.
- Haematococcus alga extract ASTOTS-S manufactured by Takeda Paper Co., Ltd. was used.
- lecithin (derived from soybean) Reion P (trade name) manufactured by Riken Vitamin Co., Ltd. was used.
- 0.05 g of the emulsion composition K-01 was added to pure water and diluted to make a total amount of 100 g.
- 0.05 g of the emulsion composition K-01 was added to 90 mL of pure water and diluted, and then the iron (II) chloride tetrahydrate was adjusted so that the amount of iron ions shown in Table 1 was obtained. The product was added, and pure water was added to make the total amount 100 g.
- emulsion composition K-01 0.05 g was added to pure water for dilution, and then an iron (II) chloride tetrahydrate in an amount corresponding to the amount of iron ions shown in Table 1 was used.
- a Japanese product and other components described in Table 1 were added so as to have the contents described in Table 1, so that the total amount was 100 g.
- compositions 1 to 7 of Examples 1 to 7 and compositions 1C to 6C of Comparative Examples 1 to 6 were prepared.
- the amount of iron ions in each composition was measured by the method described above.
- the obtained rate of change in absorbance was used as an index of stability over time (2). As the value of the rate of change in absorbance (%) is larger, the decomposition of astaxanthin at room temperature is suppressed, indicating that the stability over time is excellent. The results are shown in Table 1.
- compositions 1 to 7 which are the compositions of the examples, were stored in either room temperature (23 ° C.) or high temperature (50 ° C.) environment regardless of the amount of iron ions contained in the composition.
- room temperature 23 ° C.
- high temperature 50 ° C.
- compositions 1 to 3 as the compositions of the examples are as follows. In both cases, the stability over time is good despite containing iron ions.
- composition C5 containing dipropylene glycol the stability of astaxanthin is markedly deteriorated due to an increase in iron ions that are considered to be derived from dipropylene glycol.
- compositions 4 to 6 of Examples 4 to 6 containing an iron chelating agent contained dipropylene glycol and contained the same amount of iron ions as the composition C5. The stability over time is very good.
- composition 7 of Example 7 in which the iron chelating agent and the water-soluble antioxidant are used in combination is stable over time in comparison with the composition C5 of Comparative Example 5 that does not contain the iron chelating agent and the water-soluble antioxidant. Is very good. Furthermore, the composition 7 contains only a water-soluble antioxidant and has good temporal stability in comparison with the composition C6 of Comparative Example 6 that does not contain an iron chelator.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
また、本発明第2の観点は、アスタキサンチンの分解抑制方法を提供することを課題とする。
<1> 少なくとも、アスタキサンチン、20μg/L以上の鉄イオン、及び鉄キレート剤を含有するアスタキサンチン含有水系組成物。
<2> 更に、ジプロピレングリコールを含有する<1>に記載のアスタキサンチン含有水系組成物。
<3> 前記鉄キレート剤が、鉄キレート剤が、クエン酸若しくはその塩、エチレンジアミン四酢酸(EDTA)若しくはその塩、エチドロン酸若しくはその塩、ジエチレントリアミン五酢酸(DTPA若しくはその塩)、ヒドロキシエチレンジアミン三酢酸(HEDTA)若しくはその塩、エチレンジアミン-N,N,N’,N’-テトラメチレンホスホン酸(EDTMP)若しくはその塩、及び酒石酸若しくはその塩からなる群から選択される少なくとも1種である<1>又は<2>に記載のアスタキサンチン含有水系組成物。
<4> 更に、水溶性酸化防止剤を含有する<1>~<3>のいずれか1項に記載のアスタキサンチン含有水系組成物。
<5> <1>~<4>のいずれか1項に記載のアスタキサンチン含有水系組成物を含む化粧料。
<6> 少なくとも、アスタキサンチン、及び20μg/L以上の鉄イオンを含有する水系組成物中に、鉄キレート剤を含有させるアスタキサンチンの分解抑制方法。
<7> 更に、ジプロピレングリコールを含有する<6>に記載のアスタキサンチンの分解抑制方法。
<8> 前記鉄キレート剤が、クエン酸若しくはその塩、エチレンジアミン四酢酸(EDTA)、エチドロン酸、ジエチレントリアミン五酢酸(DTPA)、ヒドロキシエチレンジアミン三酢酸(HEDTA)、エチレンジアミン-N,N,N’,N’-テトラメチレンホスホン酸(EDTMP)、及び酒石酸からなる群から選択される少なくとも1種である<6>又は<7>に記載のアスタキサンチンの分解抑制方法。
<9> 前記水系組成物が、更に、水溶性酸化防止剤を含有する<6>~<8>のいずれか1項に記載のアスタキサンチンの分解抑制方法。
前記第2の観点によれば、アスタキサンチンの分解抑制方法を提供することができる。
本発明のアスタキサンチン含有水系組成物(以下、単に「水系組成物」とも称する。)は、少なくとも、アスタキサンチン、20μg/L以上の鉄イオン、及び鉄キレート剤を含有することを特徴とする。
また、本明細書において「~」を用いて示された数値範囲は、「~」の前後に記載される数値をそれぞれ最小値及び最大値として含む範囲を示す。
また、本発明において、組成物中の各成分の量について言及する場合、組成物中に各成分に該当する物質が複数存在する場合には、特に断らない限り、組成物中に存在する当該複数の物質の合計量を意味する。
本発明の水系組成物が含有するアスタキサンチンは、酸化防止効果、抗炎症効果、皮膚老化防止効果、美白効果などを有し、優れたエモリエント効果、皮膚の老化防止効果や酸化防止効果を付与することができる成分として知られている。
なお、本発明に「アスタキサンチン」とは、アスタキサンチン及びアスタキサンチンのエステル等の誘導体の双方を包含する(以下、適宜「アスタキサンチン類」とも称する。)。
前記天然物としては、例えば、赤色酵母ファフィア、緑藻ヘマトコッカス、海洋性細菌、オキアミ等が挙げられる。また、その培養物からの抽出物等からの抽出物を挙げることができる。
アスタキサンチン類は、アスタキサンチン類を含有する天然物から分離・抽出(さらに必要に応じて適宜精製してもよい。)したアスタキサンチン含有オイルとして、本発明の水系組成物に含まれていてもよい。
ヘマトコッカス藻抽出物(ヘマトコッカス藻由来色素)は、オキアミ由来の色素や、合成されたアスタキサンチンとはエステルの種類、及び、その含有率の点で異なることが知られている。
前記アスタキサンチン類としては、ヘマトコッカス藻から抽出されたもの(ヘマトコッカス藻抽出物ともいう。)が、品質、生産性の点から特に好ましい。
さらに詳細な説明は、「アスタキサンチンの化学」、2005年、インターネット〈URL:http://www.astaxanthin.co.jp/chemical/basic.htm〉に記載されている。
本発明の水系組成物には、20μg/L以上の鉄イオンが含まれる。
アスタキサンチンを含有する水系組成物は、20μg/L以上の鉄イオンを含有する場合に、アスタキサンチンの分解が著しく進行し、水系組成物の経時安定性が実用上問題となる程度に損なわれる。特に、50μg/L以上の鉄イオンの含有は、アスタキサンチンの含有による効果が殆ど得られない程度に、アスタキサンチンの分解を進行させてしまうが、本発明の水系組成物は、このような量の鉄イオンを含有する場合であっても、優れた経時安定性を発揮する。
本発明の水系組成物が含有する鉄イオン量の上限値に制限はないが、水系組成物が含有する他の成分の機能を考慮すると、その上限値は200μg/Lである。
本発明の水系組成物が含有する鉄キレート剤としては、鉄イオンとキレート結合を形成しうる化合物であればよい。
また、水系組成物の全質量に対する鉄キレート剤の含有量としては、0.001質量%~10質量%の範囲が好ましく、0.01質量%~3質量%の範囲がより好ましく、0.1質量%~1質量%の範囲が更に好ましい。
本発明の水系組成物は、更に、水溶性酸化防止剤を含有することが好ましい。
水溶性酸化防止剤を含有することにより、水系組成物の経時安定性をより向上させることができる。
アスコルビン酸又はアスコルビン酸誘導体又はその塩としては、L-アスコルビン酸、L-アスコルビン酸Na、L-アスコルビン酸K、L-アスコルビン酸Ca、L-アスコルビン酸リン酸エステル、L-アスコルビン酸リン酸エステルのマグネシウム塩、L-アスコルビン酸硫酸エステル、L-アスコルビン酸硫酸エステル2ナトリウム塩、L-アスコルビン酸ステアリン酸エステル、L-アスコルビン酸2-グルコシド、L-アスコルビル酸パルミチン酸エステル、テトライソパルミチン酸L-アスコルビル等が挙げられる。
これらのうち、L-アスコルビン酸リン酸エステルのマグネシウム塩が特に好ましい。
ポリフェノール類からなる化合物群としては、フラボノイド類(カテキン、アントシアニン、フラボン配糖体、イソフラボン配糖体、フラバン配糖体、フラバノン、ルチン配糖体)、フェノール酸類(クロロゲン酸、エラグ酸、没食子酸、没食子酸プロピル)、リグナン配糖体類、クルクミン配糖体類、クマリン類、などが挙げられる。また、これらの化合物は、天然物由来の抽出物中に多く含まれるため、抽出物という状態で利用することができる。
本発明の水系組成物は、更に多価アルコールを含有してもよい。
多価アルコールは、保湿機能や粘度調整機能等を有している。
また、多価アルコールは、本発明の水系組成物がエマルション組成物組成物である場合には、水と油脂成分との界面張力を低下させ、界面を広がりやすくし、微細で、かつ、安定なエマルション組成物粒子を形成しやすくする機能も有している。従って、本発明の水系組成物が多価アルコールを含有することは、本発明の水系組成物をエマルション組成物組成物として構成する場合において、エマルション組成物粒子径がより小さくなり、かつ該粒子径が小さな状態のま長期に亘り安定して保持される観点から好ましい。
また、多価アルコールの添加により、本発明の水系組成物の水分活性を下げることができ、微生物の繁殖を抑えることができる。
多価アルコールとしては、例えば、グリセリン、ジグリセリン、トリグリセリン、ポリグリセリン、3-メチル-1,3-ブタンジオール、1,3-ブチレングリコール、イソプレングリコール、ポリエチレングリコール、1,2-ペンタンジオール、1,2-ヘキサンジオール、プロピレングリコール、ジプロピレングリコール、ポリプロピレングリコール、エチレングリコール、ジエチレングリコール、ペンタエリスリトール、ネオペンチルグリコール、マルチトール、還元水あめ、蔗糖、ラクチトール、パラチニット、エリスリトール、ソルビトール、マンニトール、キシリトール、キシロース、グルコース、ラクトース、マンノース、マルトース、ガラクトース、フルクトース、イノシトール、ペンタエリスリトール、マルトトリオース、ソルビタン、トレハロース、澱粉分解糖、澱粉分解糖還元アルコール等が挙げられ、これらを、単独又は複数種の混合物の形態で用いることができる。
本発明の水系組成物を、その好適な態様である水中油滴型のエマルション組成物として構成する場合、乳化剤を含有することが好ましい。
また、本発明においては、上記の高純度レシチン以外にも、水素添加レシチン、酵素分解レシチン、酵素分解水素添加レシチン、ヒドロキシレシチン等を使用することができる。これらのレシチンは、単独又は複数種の混合物の形態で用いることができる。
本発明の水系組成物においては、上述したアスタキサンチンの他に種々の油性成分を含むことができる。
本発明で使用可能な油性成分としては、水性媒体、特に水に不溶又は難溶の、油性媒体に溶解する成分であれば、特に限定は無い。なお、水性媒体に不溶とは、水性媒体100mLに対する溶解度が、25℃において、0.01g以下であることをいい、水性媒体に難溶とは、水性媒体100mLに対する溶解度が、25℃において、0.01gを超え0.1g以下であることをいう。また、本明細書における「機能性成分」とは、生体に適用した場合に、適用された生体において所定の生理学的効果の誘導が期待され得る成分を意味する。
本発明のアスタキサンチンの分解抑制方法は、アスタキサンチンを含有する水系組成物に適用されるアスタキサンチンの分解抑制方法であり、少なくとも、アスタキサンチン、及び20μg/L以上の鉄イオンを含有する水系組成物中に、鉄キレート剤を含有させることを特徴とする。
また、一旦、高濃度のアスタキサンチン含有エマルション組成物を調製し、これを水等の水性溶媒で希釈した後、鉄キレート剤、多価アルコール、水溶性酸化防止剤等の水性成分を添加することもできる。
これらの方法を採る場合、高濃度のアスタキサンチン含有エマルション組成物の希釈割合は、適宜に選択することが可能であり、10倍以上200倍以下が好ましく、20倍以上150倍以下が更に好ましく40倍以上100倍以下がより好ましい。
均質バルブ型高圧ホモジナイザーとしては、ゴーリンタイプホモジナイザー(APV社製、商品名)、ラニエタイプホモジナイザー(ラニエ社製、商品名)、高圧ホモジナイザー(ニロ・ソアビ社製、商品名)、ホモゲナイザー(三和機械(株)製、商品名)、高圧ホモゲナイザー(イズミフードマシナリ(株)製、商品名)、超高圧ホモジナイザー(イカ社製、商品名)等が挙げられる。
本発明の水系組成物は、アスタキサンチンに起因した各種機能性に優れるだけではなく、経時安定性に優れている。このため、アスタキサンチン及び組成物中に含有される他の成分が有する機能に応じた種々の用途に、そのまま又は成分材料として好ましく用いられる。
本発明のアスタキサンチン含有分散物を、皮膚外用剤、化粧品に使用する場合、必要に応じて、医薬品や化粧品に添加可能な成分を適宜添加することができる。
下記の成分を、70℃で加熱しながら1時間溶解して、水相組成物を得た。
・ショ糖オレイン酸エステル 13g
・モノオレイン酸デカグリセリル(HLB=12) 25g
・グリセリン 500g
・純水 332g
また、下記成分を、70℃で加熱しながら1時間溶解して、油相組成物を得た。
・ヘマトコッカス藻抽出物
(アスタキサンチン類含有率20質量%) 40g
・レシチン(大豆由来) 90g
その後、乳化物を平均孔径1μmのミクロフィルターでろ過して、アスタキサンチン含有エマルション組成物K-01を調製した。
ショ糖オレイン酸エステルとしては、三菱化学フーズ株式会社製リョートーシュガーエステルO-1670(HLB=15、商品名)、モノオレイン酸デカグリセリルとしては、日光ケミカルズ株式会社製NIKKOL Decaglyn 1-O(HLB=12、商品名)を使用した。ヘマトコッカス藻抽出物としては、武田紙器株式会社製ASTOTS-Sを使用した。レシチン(大豆由来)としては、理研ビタミン株式会社製のレシオンP(商品名)を使用した。
比較例1については、0.05gのエマルション組成物K-01を、純水に添加して希釈し、総量を100gとした。
比較例2~4については、0.05gのエマルション組成物K-01を純水90mLに添加して希釈した後、表1に記載の鉄イオン量となるように塩化鉄(II)四水和物を添加し、更に純水を加えて総量を100gとした。
塩化鉄(II)四水和物としては、和光純薬株式会社製の塩化鉄(II)四水和物、クエン酸としては、和光純薬株式会社製のクエン酸、EDTA・2Naとしては、和光純薬株式会社製のエデト酸ナトリウム水和物「製造専用」、エチドロン酸Naとしては、キレスト株式会社製の「キレストPH-210」(商品名)を使用した。また、ジプロピレングリコール(DPG)としては、ADEKA社製DPG-RF、リン酸L-アスコルビルマグネシウム(APM)としては、昭和電工株式会社製アスコルビン酸「PM」(商品名)を使用した。
1.経時安定性評価(1)
経時安定性評価(1)では、実施例1~7で得られた組成物1~7、及び比較例1~6で得られた組成物1C~6Cについて、高温(50℃)で保存した前後における吸光度を測定することで、アスタキサンチンの経時安定性を評価した。
詳細には、組成物1~7及び組成物1C~6Cを、蓋付きガラス瓶(日電理科硝子社製SV-15)に15mLずつ入れたものを各1本ずつ用意した。次いで、各蓋付きガラス瓶を、高温(50℃)に保たれた恒温槽中で6日間保存した。
保存前後の各組成物を10mmセルに入れ、UV-VIBLEスペクトルフォトメーターUV-2550((株)島津製作所製、商品名)を使用して、波長478nmにおける吸光度を測定し、保存前後における吸光度変化率(%)を、下記式(1)により算出した。得られた吸光度変化率を経時安定性(1)の指標とした。
吸光度変化率(%)=保存後の吸光度/保存前の吸光度×100 式(1)
吸光度変化率(%)の値が大きい程、高温環境下におけるアスタキサンチンの分解が抑制されており、経時安定性に優れていることを示す。
結果を表1に示す。
経時安定性評価(2)では、実施例1~7で得られた組成物1~7、及び比較例1~6で得られた組成物1C~6Cについて、室温(23℃)で保存した前後における吸光度を測定することで、アスタキサンチンの経時安定性を評価した。
詳細には、経時安定性評価(1)における蓋付きガラス瓶の保存条件を、室温(23℃)に保たれた恒温槽中で3ヵ月間保存することに変更した以外は、経時安定性評価(1)と同様にして、組成物1~7及び組成物1C~6Cを入れた蓋付きガラス瓶を保存した。各組成物の保存前後における吸光度を測定し、変化率(%)を算出した。得られた吸光度変化率を経時安定性(2)の指標とした。
吸光度変化率(%)の値が大きい程、室温下におけるアスタキサンチンの分解が抑制されており、経時安定性に優れていることを示す。
結果を表1に示す。
比較例の組成物である、塩化鉄(II)四水和物を添加していない組成物C1と、塩化鉄(II)四水和物を添加した組成物C2~C4対比からは、組成物中における鉄イオンの含有量が増加するに従って、吸光度の変化率(%)が低下しており、鉄イオンの存在がアスタキサンチンの経時安定性を悪化させることが確認された。
特に、20μg/L以上の鉄イオンを含む組成物C3及びC4では、経時安定性が実用上問題となる程度に著しく悪化していることが分る。
Claims (9)
- 少なくとも、アスタキサンチン、20μg/L以上の鉄イオン、及び鉄キレート剤を含有するアスタキサンチン含有水系組成物。
- 更に、ジプロピレングリコールを含有する請求項1に記載のアスタキサンチン含有水系組成物。
- 前記鉄キレート剤が、クエン酸若しくはその塩、エチレンジアミン四酢酸(EDTA)若しくはその塩、エチドロン酸若しくはその塩、ジエチレントリアミン五酢酸(DTPA若しくはその塩)、ヒドロキシエチレンジアミン三酢酸(HEDTA)若しくはその塩、エチレンジアミン-N,N,N’,N’-テトラメチレンホスホン酸(EDTMP)若しくはその塩、及び酒石酸若しくはその塩からなる群から選択される少なくとも1種である請求項1又は請求項2に記載のアスタキサンチン含有水系組成物
- 更に、水溶性酸化防止剤を含有する請求項1~請求項3のいずれか1項に記載のアスタキサンチン含有水系組成物。
- 請求項1~請求項4のいずれか1項に記載のアスタキサンチン含有水系組成物を含む化粧料。
- 少なくとも、アスタキサンチン、及び20μg/L以上の鉄イオンを含有する水系組成物中に、鉄キレート剤を含有させるアスタキサンチンの分解抑制方法。
- 更に、ジプロピレングリコールを含有する請求項6に記載のアスタキサンチンの分解抑制方法。
- 前記鉄キレート剤が、クエン酸若しくはその塩、エチレンジアミン四酢酸(EDTA)若しくはその塩、エチドロン酸若しくはその塩、ジエチレントリアミン五酢酸(DTPA若しくはその塩)、ヒドロキシエチレンジアミン三酢酸(HEDTA)若しくはその塩、エチレンジアミン-N,N,N’,N’-テトラメチレンホスホン酸(EDTMP)若しくはその塩、及び酒石酸若しくはその塩からなる群から選択される少なくとも1種である請求項6又は請求項7に記載のアスタキサンチンの分解抑制方法。
- 前記水系組成物が、更に、水溶性酸化防止剤を含有する請求項6~請求項8のいずれか1項に記載のアスタキサンチンの分解抑制方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11812223.3A EP2599473A4 (en) | 2010-07-28 | 2011-07-01 | ASTAXANO-CONTAINING AQUEOUS COMPOSITION, COSMETIC PREPARATION, AND METHOD FOR SUPPRESSING THE DEGRADATION OF ASTAXANTHINE |
KR1020137002068A KR20130097143A (ko) | 2010-07-28 | 2011-07-01 | 아스타크산틴 함유 수계 조성물, 화장료, 및 아스타크산틴의 분해 억제 방법 |
CN201180036036.XA CN103025306B (zh) | 2010-07-28 | 2011-07-01 | 含虾青素的水系组合物、化妆品和虾青素的分解抑制方法 |
US13/748,692 US20130131184A1 (en) | 2010-07-28 | 2013-01-24 | Astaxanthin-containing aqueous composition, cosmetic preparation, and method for suppressing decomposition of astaxanthin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-169443 | 2010-07-28 | ||
JP2010169443A JP5535808B2 (ja) | 2010-07-28 | 2010-07-28 | アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/748,692 Continuation US20130131184A1 (en) | 2010-07-28 | 2013-01-24 | Astaxanthin-containing aqueous composition, cosmetic preparation, and method for suppressing decomposition of astaxanthin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012014630A1 true WO2012014630A1 (ja) | 2012-02-02 |
Family
ID=45529849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/065228 WO2012014630A1 (ja) | 2010-07-28 | 2011-07-01 | アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20130131184A1 (ja) |
EP (1) | EP2599473A4 (ja) |
JP (1) | JP5535808B2 (ja) |
KR (1) | KR20130097143A (ja) |
CN (1) | CN103025306B (ja) |
WO (1) | WO2012014630A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013118533A1 (ja) * | 2012-02-08 | 2015-05-11 | 日油株式会社 | パラフィン混合物およびその製造方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6367586B2 (ja) * | 2013-03-27 | 2018-08-01 | 株式会社コーセー | 透明ゲル状組成物 |
EP3011972B1 (en) * | 2013-06-19 | 2019-10-23 | SBI Pharmaceuticals Co., Ltd. | Medicinal composition for promoting synthesis of protoporphyrin ix |
JP2016044150A (ja) * | 2014-08-25 | 2016-04-04 | 富士フイルム株式会社 | 化粧料 |
CN105055368A (zh) * | 2015-09-23 | 2015-11-18 | 湖北雅仕达生物技术有限公司 | 促进胃肠道吸收虾青素的口服制品及制备方法 |
CN111568858A (zh) * | 2020-04-30 | 2020-08-25 | 佛山科学技术学院 | 一种虾青素水溶液的制备方法 |
CN111671716A (zh) * | 2020-07-22 | 2020-09-18 | 广州蛋壳网络科技有限公司 | 一种抗氧化提亮肤色组合物及在化妆品中的应用 |
CN111793014B (zh) * | 2020-07-27 | 2021-07-13 | 中国海洋大学 | 一种制备水溶性虾青素的方法及由其制得的虾青素水溶液 |
CN112645860A (zh) * | 2021-02-01 | 2021-04-13 | 常州市第二人民医院 | 叶黄素制备虾青素的方法 |
CN113304076B (zh) * | 2021-05-21 | 2023-03-10 | 哈尔滨北星药业有限公司 | 一种用于提亮肤色的组合物、制剂及其制备方法和应用 |
CN114081069A (zh) * | 2021-11-11 | 2022-02-25 | 光明乳业股份有限公司 | 一种含虾青素的乳制品及其制备方法 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0215017A (ja) * | 1988-07-01 | 1990-01-18 | Kansai Paint Co Ltd | 色白化粧料 |
JPH0249091A (ja) | 1988-08-11 | 1990-02-19 | Suntory Ltd | アスタキサンチン含有組成物 |
JPH06264055A (ja) | 1993-03-16 | 1994-09-20 | K I Kasei Kk | カロテノイド系色素の安定化方法、カロテノイド系色素の安定化組成物、及び当該方法により安定化されたカロテノイド系色素を含有する飼料 |
JPH09143063A (ja) | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
JP2000136123A (ja) | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
JP2000342657A (ja) * | 1999-03-30 | 2000-12-12 | Taisho Pharmaceut Co Ltd | ミノキシジル製剤製造設備 |
JP2002128651A (ja) | 2000-10-25 | 2002-05-09 | Kose Corp | 光老化抑制剤およびそれを含有することを特徴とする皮膚外用剤 |
JP2005187329A (ja) * | 2003-12-24 | 2005-07-14 | Lion Corp | 口腔用組成物 |
JP2008074717A (ja) | 2006-09-19 | 2008-04-03 | Fujifilm Corp | カロテノイド含有エマルジョン組成物、その製造方法、該組成物を含む食品、外用剤およびその製造方法 |
JP2008179619A (ja) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | アスタキサンチン含有組成物 |
JP2008239609A (ja) * | 2007-02-28 | 2008-10-09 | Kose Corp | 皮膚外用剤 |
WO2009048120A1 (ja) * | 2007-10-11 | 2009-04-16 | Nisshin Pharma Inc. | アスタキサンチン含有水溶性組成物 |
JP2010169443A (ja) | 2009-01-20 | 2010-08-05 | Dainippon Printing Co Ltd | 音響信号に対する情報の埋め込み装置および音響信号を利用した位置検出装置 |
-
2010
- 2010-07-28 JP JP2010169443A patent/JP5535808B2/ja active Active
-
2011
- 2011-07-01 WO PCT/JP2011/065228 patent/WO2012014630A1/ja active Application Filing
- 2011-07-01 KR KR1020137002068A patent/KR20130097143A/ko not_active Application Discontinuation
- 2011-07-01 EP EP11812223.3A patent/EP2599473A4/en not_active Withdrawn
- 2011-07-01 CN CN201180036036.XA patent/CN103025306B/zh active Active
-
2013
- 2013-01-24 US US13/748,692 patent/US20130131184A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0215017A (ja) * | 1988-07-01 | 1990-01-18 | Kansai Paint Co Ltd | 色白化粧料 |
JPH0249091A (ja) | 1988-08-11 | 1990-02-19 | Suntory Ltd | アスタキサンチン含有組成物 |
JPH06264055A (ja) | 1993-03-16 | 1994-09-20 | K I Kasei Kk | カロテノイド系色素の安定化方法、カロテノイド系色素の安定化組成物、及び当該方法により安定化されたカロテノイド系色素を含有する飼料 |
JPH09143063A (ja) | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
JP2000136123A (ja) | 1998-10-28 | 2000-05-16 | Kose Corp | 皮膚外用剤 |
JP2000342657A (ja) * | 1999-03-30 | 2000-12-12 | Taisho Pharmaceut Co Ltd | ミノキシジル製剤製造設備 |
JP2002128651A (ja) | 2000-10-25 | 2002-05-09 | Kose Corp | 光老化抑制剤およびそれを含有することを特徴とする皮膚外用剤 |
JP2005187329A (ja) * | 2003-12-24 | 2005-07-14 | Lion Corp | 口腔用組成物 |
JP2008074717A (ja) | 2006-09-19 | 2008-04-03 | Fujifilm Corp | カロテノイド含有エマルジョン組成物、その製造方法、該組成物を含む食品、外用剤およびその製造方法 |
JP2008179619A (ja) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | アスタキサンチン含有組成物 |
JP2008239609A (ja) * | 2007-02-28 | 2008-10-09 | Kose Corp | 皮膚外用剤 |
WO2009048120A1 (ja) * | 2007-10-11 | 2009-04-16 | Nisshin Pharma Inc. | アスタキサンチン含有水溶性組成物 |
JP2010169443A (ja) | 2009-01-20 | 2010-08-05 | Dainippon Printing Co Ltd | 音響信号に対する情報の埋め込み装置および音響信号を利用した位置検出装置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2599473A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013118533A1 (ja) * | 2012-02-08 | 2015-05-11 | 日油株式会社 | パラフィン混合物およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2012031067A (ja) | 2012-02-16 |
CN103025306A (zh) | 2013-04-03 |
KR20130097143A (ko) | 2013-09-02 |
CN103025306B (zh) | 2015-09-30 |
JP5535808B2 (ja) | 2014-07-02 |
EP2599473A1 (en) | 2013-06-05 |
EP2599473A4 (en) | 2014-01-15 |
US20130131184A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5535808B2 (ja) | アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法 | |
EP1927287B1 (en) | Emulsion composition, and foods and cosmetics containing the emulsion composition | |
EP2380552B1 (en) | Emulsion composition, and uses of the emulsion composition | |
JP5459939B2 (ja) | カロチノイド含有エマルジョン組成物、その製造方法、それを含む食品及び化粧品 | |
JP4302159B2 (ja) | エマルション組成物、該エマルション組成物を含む食品及び化粧品 | |
JP5936796B1 (ja) | 乳化組成物 | |
KR20140040754A (ko) | 아스타크산틴 함유 조성물 및 그 제조 방법, 그리고 화장료 | |
EP2982364B1 (en) | Oil-in-water emulsion composition | |
JP4869979B2 (ja) | コーヒー豆抽出物含有水性組成物、容器詰飲料、コーヒー豆抽出物含有水性組成物の製造方法、及びコーヒー豆抽出物の沈殿防止方法 | |
JP2009143900A (ja) | 乳化組成物 | |
JP2009142180A (ja) | 容器詰飲料 | |
JP2008074717A (ja) | カロテノイド含有エマルジョン組成物、その製造方法、該組成物を含む食品、外用剤およびその製造方法 | |
JP2009114184A (ja) | 粉末製剤、食品組成物、化粧品組成物及び医薬品組成物 | |
JP2008280257A (ja) | エマルション組成物及びポリフェノール化合物の凝集防止方法 | |
KR101669831B1 (ko) | 수중 유형 에멀젼 조성물 | |
JP5631941B2 (ja) | 容器詰飲料 | |
JP5878590B2 (ja) | 容器詰飲料 | |
JP2008174537A (ja) | 粉末組成物並びに、これを含む食品組成物、化粧品組成物及び医薬品組成物 | |
JP2008237057A (ja) | 粉末組成物及びその製造方法 | |
JP2008072905A (ja) | カロテノイド含有エマルジョン組成物、その製造方法、該組成物を含む食品および化粧品 | |
JP5283458B2 (ja) | 粉末組成物、食品組成物、化粧品組成物及び医薬品組成物 | |
JP2012040018A (ja) | 容器詰飲料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180036036.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11812223 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011812223 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137002068 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |